Kosan Buy Puts BMS Front And Center In HSP90 Race, Strengthens Epothilone Position
This article was originally published in The Pink Sheet Daily
Executive Summary
BMS gains several clinical-stage oncology programs with agreement to acquire Kosan for $190 million.